NORD is encouraging patient advocates to call, email and tweet their Senators in support of the Orphan Drug Tax Credit (ODTC). Yesterday, the House passed a tax reform bill that would get rid of the ODTC, a critical incentive for orphan drug creation. These provisions are now being considered by the Senate. The ODTC allows drug manufacturers to claim a tax credit of 50 percent of the qualified costs of clinical research and drug testing of orphan drugs (drugs for diseases affecting 200,000 Americans or fewer). The ODTC is part of a package of provisions enacted in 1983 in the Orphan Drug Act (ODA) that provides incentives for drug companies to develop products for rare diseases. This legislation has been extremely successful.
https://rareadvocates.org/wp-content/uploads/2016/04/email-white.png 270 800 Sabah Bhatnagar https://rareadvocates.org/wp-content/uploads/2020/01/RDLA-logo-with-tag-white-rev.png Sabah Bhatnagar2017-10-23 10:59:512017-12-08 16:30:02NORD is Asking Patient Advocates to Encourage Their Senators to Save the Orphan Drug Tax Credit